The drug candidates in Apollomics' pipeline can be categorized into three groups based on their mechanisms of action: tumor inhibitors, anti-cancer enhancers, and immuno-oncology drugs. This enables the company to develop potential synergistic combination therapies that address unmet needs in cancer treatment. The company's website provides more information about their work.